Literature DB >> 16372493

Genetic predisposition to cancer: the consequences of a delayed diagnosis of Gorlin syndrome.

G Mitchell1, P A Farndon, P Brayden, V A Murday, R A Eeles.   

Abstract

This report outlines a case of Gorlin syndrome, the diagnosis of which was delayed for many years, and raises a number of important issues. These are the spectrum of late radiotherapy effects, particularly after treatment for benign disease, and the importance of considering the possibility of the presence of a genetic syndrome predisposing to cancer in all individuals before starting any treatment. As our knowledge of genetic syndromes expands, this will become increasingly important. Finally, if a genetic predisposition to cancer is suspected, consideration should be given to obtaining a blood sample from the affected patient for DNA storage, particularly if their prognosis is limited. Currently, genetic testing can only be instituted in most families by first obtaining DNA from an individual affected by cancer, as most genetic mutations are unique to a family. If all relatives with cancer have died, then, at this time, genetic testing cannot usually be attempted, unless such samples have previously been stored.

Entities:  

Mesh:

Year:  2005        PMID: 16372493     DOI: 10.1016/j.clon.2005.07.014

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  3 in total

1.  Gorlin syndrome.

Authors:  Jane E Hooper; Jonathan Schofield; Handrean Soran; Richard W Whitehouse
Journal:  BMJ Case Rep       Date:  2013-10-30

2.  Improving service evaluation in clinical genetics: identifying effects of genetic diseases on individuals and families.

Authors:  Marion McAllister; Katherine Payne; Stuart Nicholls; Rhona MacLeod; Dian Donnai; Linda M Davies
Journal:  J Genet Couns       Date:  2007-02-13       Impact factor: 2.537

3.  Basal cell nevus syndrome (Gorlin-Goltz syndrome): genetic predisposition, clinical picture and treatment.

Authors:  Henryk Witmanowski; Paweł Szychta; Katarzyna Błochowiak; Arkadiusz Jundziłł; Rafał Czajkowski
Journal:  Postepy Dermatol Alergol       Date:  2017-08-02       Impact factor: 1.837

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.